The strong results and reaffirmed guidance suggest continued momentum in Ligand's royalty portfolio. Traders should monitor upcoming catalysts from partner programs including Filspari, Ohtuvayre, and Tzield, which could provide additional upside.
Price Chart
Executive Summary
Ligand Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by a 48% increase in royalty revenue. The company achieved GAAP net income of $124.5 million and core adjusted EPS of $8.13, exceeding prior guidance. Ligand is reaffirming its 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS.
Key Financial Metrics
Key Facts
- Full year 2025 revenue was $268.1 million, up from $167.1 million in 2024, driven by 48% growth in royalty revenue to $161.0 million
- Core adjusted EPS was $8.13 for 2025, exceeding initial guidance by approximately 30%
- GAAP net income was $124.5 million, a significant improvement from a $4.0 million net loss in 2024
- Company reaffirmed 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS
- Cash, cash equivalents, and short-term investments totaled $733.5 million as of December 31, 2025
Financial Impact
Revenue increased 60.4% year-over-year to $268.1 million, with core adjusted net income growing 52.2% to $165.1 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Royalties | $161.0M | +48.0% |
| Captisol | $40.2M | +30.1% |
| Contract revenue and income | $66.9M | +143.7% |
Risk Factors
- Future performance depends on partner drug development and commercialization success
- The $28.6 million gain from the Pelthos sale was a one-time item and not indicative of recurring performance
- Company faces risks related to partner program discontinuations and impairments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000886163-26-000003 |
| Document: lgnd-20260226.htm | 0000886163-26-000003 |
| Document: 0000886163-26-000003-index-headers.html | 0000886163-26-000003 |
| Document: 0000886163-26-000003-index.html | 0000886163-26-000003 |
| Document: 0000886163-26-000003.txt | 0000886163-26-000003 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | Insider Cluster | $276.98 $298.50 | ▲ +7.77% | ▲ +5.66% | $302.96 (+9.38%) |
Aug 14, 2026 6w ago | Insider Cluster | $291.77 $280.18 | ▼ −3.97% | ▼ −2.78% | $302.96 (+3.84%) |
Aug 6, 2026 8w ago | 8-K | $300.14 $288.82 | ▼ −3.77% | ▼ −4.98% | $302.96 (+0.94%) |
Jun 25, 2026 14w ago | 8-K | $303.59 $319.55 | ▲ +5.26% | ▲ +3.09% | $302.96 (−0.21%) |
Jun 18, 2026 15w ago | Insider Cluster | $274.88 $295.92 | ▲ +7.65% | ▲ +9.32% | $302.96 (+10.22%) |
Jun 16, 2026 15w ago | Insider Cluster | $255.25 $279.44 | ▲ +9.48% | ▲ +11.71% | $302.96 (+18.69%) |
Jun 12, 2026 15w ago | Insider Cluster | $253.25 $262.17 | ▲ +3.52% | ▲ +4.91% | $302.96 (+19.63%) |
May 1, 2026 22w ago | Insider Cluster | $227.44 $221.41 | ▼ −2.65% | ▼ −5.00% | $302.96 (+33.20%) |
Apr 14, 2026 24w ago | Press Release | $232.34 $226.67 | ▼ −2.44% | ▼ −3.83% | $302.96 (+30.40%) |
Feb 26, 2026 31w ago | 8-K | $196.17 $206.27 | ▲ +5.15% | ▲ +6.28% | $302.96 (+54.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access